Keros Therapeutics, Inc. — Income Charts
8 quarters of history · ending 2025-12-31 · SEC EDGAR
Source:10-K · 10-Q
Revenue, Gross Profit, Operating Income & Net Income
Margin (%)
Operating Expenses
Income Breakdown
Revenue
$380K
R&D↓-60.7% -$28M
$18M
D&A↑+20.5% +$68K
$400K
Operating Income↑+73.8% +$43M
$-15M
EBITDA↑+20.5% +$68K
$400K
Interest Expense
$0
Other Income/Expense↑+17.2% +$979K
$7M
Pretax Income↑+83.6% +$44M
$-9M
Tax Provision
$-1M
Net Income↑+86.3% +$46M
$-7M
Operating Margin
-108.9%
Net Margin
-51.5%
Effective Tax Rate↑+16.4pts
16.4%
ETR (Continuing Operations)↑+5.5pts
5.3%
ETR Federal Statutory↑+0.0pts
21.0%
ETR State + Local (pp)↓-8.0pts
0.8%
Operating Lease Cost↑+67.1% +$710K
$2M
Revenue YoY Variation
-100.0%
Income YoY Variation↑+109.3pts
73.8%
Revenue QoQ Variation
-97.3%
Income QoQ Variation↑+77.7pts
61.4%